I
Ian Judson
Researcher at Institute of Cancer Research
Publications - 501
Citations - 43836
Ian Judson is an academic researcher from Institute of Cancer Research. The author has contributed to research in topics: Sarcoma & Soft tissue sarcoma. The author has an hindex of 95, co-authored 492 publications receiving 39772 citations. Previous affiliations of Ian Judson include Lincoln's Inn & European Organisation for Research and Treatment of Cancer.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri,Allan T. van Oosterom,Christopher R. Garrett,Martin E. Blackstein,Manisha H. Shah,Jaap Verweij,Grant A. McArthur,Ian Judson,Michael Heinrich,Jeffrey A. Morgan,Jayesh Desai,Christopher D.M. Fletcher,Suzanne George,Carlo L. Bello,Xin Huang,Charles M. Baum,Paolo G. Casali +16 more
TL;DR: A randomised, double-blind, placebo-controlled, multicentre, international trial to assess tolerability and anticancer efficacy of sunitinib in patients with advanced gastrointestinal stromal tumour, noting significant clinical benefit, including disease control and superior survival.
Journal ArticleDOI
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
Ah Calvert,David Richard Newell,L A Gumbrell,S O'Reilly,M Burnell,F. E. Boxall,Zahid H Siddik,Ian Judson,Martin Gore,E Wiltshaw +9 more
TL;DR: The formula provides a simple and consistent method of determining carboplatin dose in adults and will not be influenced by previous or concurrent myelosuppressive therapy or supportive measures, and is applicable to combination and high-dose studies as well as conventional single-agent therapy, although the target AUC will need to be redefined for combination chemotherapy.
Journal ArticleDOI
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T. A. van der Graaf,Jean-Yves Blay,Sant P. Chawla,Dong Wan Kim,B. Bui-Nguyen,Paolo G. Casali,Patrick Schöffski,Massimo Aglietta,Arthur P. Staddon,Yasuo Beppu,Axel Le Cesne,Hans Gelderblom,Ian Judson,Nobuhito Araki,M. Ouali,Sandrine Marreaud,Rachel Hodge,Mohammed R. Dewji,Corneel Coens,George D. Demetri,Christopher D.M. Fletcher,Angelo Paolo Dei Tos,Peter Hohenberger +22 more
TL;DR: This phase 3 study investigated the effect of pazopanib on progression-free survival in patients with metastatic non-adipocytic soft-tissue sarcoma after failure of standard chemotherapy.
Journal ArticleDOI
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial*
Jaap Verweij,Paolo G. Casali,John Zalcberg,A. Lecesne,Peter Reichardt,Jean-Yves Blay,Rolf D. Issels,Allan T. van Oosterom,Pancras C.W. Hogendoorn,Martine Van Glabbeke,Rossella Bertulli,Ian Judson +11 more
TL;DR: If response induction is the only aim of treatment, a daily dose of400 mg of imatinib is sufficient; however, a dose of 400 mg twice a day achieves significantly longer progression-free survival.
Journal ArticleDOI
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.
Allan T. van Oosterom,Ian Judson,Jaap Verweij,Sigrid Stroobants,Eugenio Donato di Paola,Sasa Dimitrijevic,Marc Martens,Andrew Webb,Raf Sciot,Martine Van Glabbeke,Sandra Silberman,Ole S. Nielsen +11 more
TL;DR: Impatinib at a dose of 400 mg twice daily is well tolerated during the first 8 weeks, side-effects diminish with continuing treatment, and it has significant activity in patients with advanced GISTs.